Biovica, active in blood-based cancer monitoring, has signed an order with a total value of 2.3 MSEK for TKa testing services within its Pharma Services business. The work order is signed with a UK-based pharma/biotech company to be used in a phase I/II clinical study in patients with advanced solid tumors being treated with a next generation CDK inhibitor.
The order follows a smaller proof-of-concept study rendering good results leading to this larger clinical-study-work-order. TKa will be used for repetitive testing during the trial. The work order has a value of 2 MSEK plus 0.3 MSEK for additional services. The company signed a master service agreement (MSA) with Biovica in 2024.
“We are pleased to see the strong development in our Pharma Services business. TKa is now used in 15 ongoing trials, increasing the likelihood of TKa being validated as a companion biomarker for patient treatment monitoring and optimization. Another MSA-customer, who is also developing next generation CDK inhibitors in phase I/II, just signed its 8th work order with us. Large and repeat business makes me confident about the future”, said Henrik Winther, SVP, Business Development at Biovica.